J&J, Vertex Partner To Commercialize VX-950 For Hepatitis C

J&J gains rights to the protease inhibitor in certain international markets with a $165 mil. up-front payment to Vertex.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet